This is a Spanish translation of the October 31, 2024 version of UVA-F-2028. This case examines the July 2016 decision by Israeli pharmaceutical Teva Pharmaceuticals Industries Limited (Teva) to raise USD19.5 billion in cash through a multicurrency bond offering to finance an acquisition that would firmly solidify Teva’s position as the largest generic pharmaceuticals manufacturer in the world. In light of a pending acquisition of Actavis, the generic drug manufacturing arm of Irish-US pharmaceutical Allergen Inc. (Allergen), Teva management planned to sell USD19.5 billion in bonds at various maturities from 2 years to 30 years and in three different currencies (US dollar, euro, and Swiss franc). In the context of a significant cross-border acquisition, students are introduced to the pricing of corporate bonds with the invitation to price (specify the coupon rate) on Teva’s bold global offering. This case is taught at Darden in the core finance curriculum of the MBA program in order to introduce the concept of the risk premium, risk, and the mechanics of pricing of corporate bonds.